Cargando…
Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients
Current practice guidelines for the treatment of COPD recommend the use of combined inhaled corticosteroids and long-acting bronchodilators in severe and very severe patients (GOLD stages III and IV). The aim of this study was to evaluate, through a simulation model, the economic consequences of thi...
Autores principales: | Negro, Roberto Dal, Eandi, M, Pradelli, L, Iannazzo, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695615/ https://www.ncbi.nlm.nih.gov/pubmed/18044689 |
Ejemplares similares
-
Cost of persistent asthma in Italy
por: Dal Negro, Roberto W., et al.
Publicado: (2016) -
Inhaled corticosteroid dose is associated with Pseudomonas aeruginosa infection in severe COPD
por: Shafiek, Hanaa, et al.
Publicado: (2021) -
Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK
por: Kiff, Chris, et al.
Publicado: (2018) -
Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update
por: Dal Negro, Roberto W, et al.
Publicado: (2015) -
Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021)